| Assay ID | Title | Year | Journal | Article |
|---|
| AID60389 | Ex vivo thromboxane receptor (TXA2 synthase) inhibitory activity after 8 hr of oral dosing (1 mg/kg) in the dog | 1995 | Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
| Dual-acting thromboxane receptor antagonist/synthase inhibitors: synthesis and biological properties of [2-substituted-4-(3-pyridyl)-1,3-dioxan-5-yl] alkenoic acids. |
| AID212966 | In vitro inhibitory activity against human microsomal thromboxane synthase. | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. |
| AID196815 | Compound at an oral dose of 10 mg/Kg was tested ex vivo in rat after 3 hr against platelet aggregation induced by U-46,619 | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. |
| AID160938 | In vitro inhibition of platelet activating factor induced platelet aggregation in rabbit platelet rich plasma (PRP); NT means not tested | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
| Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs. |
| AID212454 | Inhibition of horse thromboxane A2 synthase evaluated as molar concentration required to reduce thromboxane B2 formed after incubating PGH-2 with platelet microsomes. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species. Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives. |
| AID228166 | Tested for the effect at 30 mg/kg through peroral route on rat serum creatinine, 24 hr after reperfusion; (p<0.05) | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
| Dibenzoxepin derivatives: thromboxane A2 synthase inhibition and thromboxane A2 receptor antagonism combined in one molecule. |
| AID212948 | In vitro for antagonistic activity against thromboxane synthase receptor | 1998 | Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
| Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compoun |
| AID60380 | Ex vivo thromboxane receptor (TXA2 synthase) inhibitory activity after 24 hr of oral dosing (1 mg/kg) in the dog | 1995 | Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
| Dual-acting thromboxane receptor antagonist/synthase inhibitors: synthesis and biological properties of [2-substituted-4-(3-pyridyl)-1,3-dioxan-5-yl] alkenoic acids. |
| AID196814 | Compound at an oral dose of 10 mg/Kg was tested ex vivo in rat after 1 hr against platelet aggregation induced by U-46,619 | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. |
| AID196708 | Protective effect was evaluated by measuring the urinary total protein by peroral administering 100 mg/kg per day for four weeks in 7 rats for four weeks. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species. Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives. |
| AID62829 | Compound at an oral dose of 1 mg/Kg was tested ex vivo in dog after 5 hr against platelet aggregation induced by U-46,619 | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. |
| AID190224 | Protective effect was evaluated by measuring the urinary albumin by peroral administering 100 mg/kg per day for four weeks in adriamycin induced proteinuria 7 rats for four weeks. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species. Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives. |
| AID212601 | Inhibitory activity against horse thromboxane A2 synthase | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species. Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives. |
| AID210346 | Activity against TXA2 synthase in bovine platelet microsome | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
| Dibenzoxepin derivatives: thromboxane A2 synthase inhibition and thromboxane A2 receptor antagonism combined in one molecule. |
| AID62828 | Compound at an oral dose of 1 mg/Kg was tested ex vivo in dog after 3 hr against platelet aggregation induced by U-46,619 | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. |
| AID93433 | In vitro inhibition of U-46,619-induced aggregation of unwashed human platelets; NT = Not tested | 1995 | Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
| Dual-acting thromboxane receptor antagonist/synthase inhibitors: synthesis and biological properties of [2-substituted-4-(3-pyridyl)-1,3-dioxan-5-yl] alkenoic acids. |
| AID213115 | In vitro for inhibitory activity against thromboxane synthase | 1998 | Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
| Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compoun |
| AID60378 | Ex vivo thromboxane receptor (TXA2 synthase) inhibitory activity after 1 hr of oral dosing (1 mg/kg) in the dog | 1995 | Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
| Dual-acting thromboxane receptor antagonist/synthase inhibitors: synthesis and biological properties of [2-substituted-4-(3-pyridyl)-1,3-dioxan-5-yl] alkenoic acids. |
| AID180669 | Reduction of lipid peroxide formed in rat brain homogenates. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species. Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives. |
| AID212964 | In vitro inhibition of thromboxane synthase (TSI) activity was determined by using human serum levels of TXB2 | 1998 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15
| Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 2. Design, synthesis, and evaluation of a novel series of phenyl oxazole derivatives. |
| AID60078 | Compound at an oral dose of 1 mg/Kg was tested ex vivo after 3 hr for inhibition of thromboxane synthase in dog | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. |
| AID227630 | Tested for the effect at 30 mg/kg through peroral route on rat blood urea nitrogen, 24 hr after reperfusion; (p<0.01) | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
| Dibenzoxepin derivatives: thromboxane A2 synthase inhibition and thromboxane A2 receptor antagonism combined in one molecule. |
| AID210337 | In vitro thromboxane receptor antagonism was determined using a human platelet binding assay | 1998 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15
| Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 2. Design, synthesis, and evaluation of a novel series of phenyl oxazole derivatives. |
| AID210469 | Inhibitory activity against thromboxane B2 formation (TXA2 synthase) by incubating prostaglandin H2 (PGH-2) with horse platelet microsomes | 1985 | Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
| Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids. |
| AID183983 | Compound at an oral dose of 10 mg/Kg was tested ex vivo after 5 hr for inhibition of thromboxane synthase in rat | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. |
| AID60207 | Compound at an oral dose of 1 mg/Kg was tested ex vivo after 5 hr for inhibition of thromboxane synthase in dog | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. |
| AID183565 | Inhibition of thromboxane B2 production in whole blood of rats 1 hr following 1 mg/kg p.o. | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
| Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives. |
| AID182007 | In vivo percent inhibition of lipid peroxidation in rat brain homogenates at 10e-6 M | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species. Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives. |
| AID62827 | Compound at an oral dose of 1 mg/Kg was tested ex vivo in dog after 1 hr against platelet aggregation induced by U-46,619 | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. |
| AID183982 | Compound at an oral dose of 10 mg/Kg was tested ex vivo after 3 hr for inhibition of thromboxane synthase in rat | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. |
| AID212775 | Inhibition of rat thromboxane A2 synthase evaluated as percent inhibition of thromboxane B2 formation after 24 hr of administration at 10 mg/kg. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species. Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives. |
| AID60077 | Compound at an oral dose of 1 mg/Kg was tested ex vivo after 1 hr for inhibition of thromboxane synthase in dog | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. |
| AID212959 | In vitro Inhibition of thromboxane synthase from human blood platelet microsomes | 1995 | Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
| Dual-acting thromboxane receptor antagonist/synthase inhibitors: synthesis and biological properties of [2-substituted-4-(3-pyridyl)-1,3-dioxan-5-yl] alkenoic acids. |
| AID179761 | In vitro inhibition of thromboxane A2 production in rat platelet-rich plasma. | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
| Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives. |
| AID160761 | In vitro inhibition of Prostaglandin I2 synthase from human blood platelet microsomes | 1995 | Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
| Dual-acting thromboxane receptor antagonist/synthase inhibitors: synthesis and biological properties of [2-substituted-4-(3-pyridyl)-1,3-dioxan-5-yl] alkenoic acids. |
| AID183550 | Inhibition of thromboxane A2 production in whole blood of rats, 4 hr after a peroral dose of 1.0 mg/kg | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
| Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives. |
| AID183843 | Ex vivo percent inhibition against serum TXB2 production after 24 hr r at dose 1 mg/kg by oral administration in rat | 1985 | Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
| Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids. |
| AID60387 | Ex vivo thromboxane receptor (TXA2 synthase) inhibitory activity after 5 hr of oral dosing (1 mg/kg) in the dog | 1995 | Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
| Dual-acting thromboxane receptor antagonist/synthase inhibitors: synthesis and biological properties of [2-substituted-4-(3-pyridyl)-1,3-dioxan-5-yl] alkenoic acids. |
| AID183564 | Inhibition of thromboxane B2 production in whole blood of rats, 1 hr after a peroral dose of 0.1 mg/kg | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
| Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives. |
| AID210487 | Tested for specific binding of radioligand [3H]U-46619 to thromboxane A2 /prostaglandin H2 receptor in guinea pig washed platelets | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
| Dibenzoxepin derivatives: thromboxane A2 synthase inhibition and thromboxane A2 receptor antagonism combined in one molecule. |
| AID228167 | Tested for the effect at 30 mg/kg through peroral route on rat serum creatinine, 48 hr after reperfusion | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
| Dibenzoxepin derivatives: thromboxane A2 synthase inhibition and thromboxane A2 receptor antagonism combined in one molecule. |
| AID60385 | Ex vivo thromboxane receptor (TXA2 synthase) inhibitory activity after 3 hr of oral dosing (1 mg/kg) in the dog | 1995 | Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
| Dual-acting thromboxane receptor antagonist/synthase inhibitors: synthesis and biological properties of [2-substituted-4-(3-pyridyl)-1,3-dioxan-5-yl] alkenoic acids. |
| AID183981 | Compound at an oral dose of 10 mg/Kg was tested ex vivo after 1 hr for inhibition of thromboxane synthase in rat | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. |
| AID183842 | Ex vivo percent inhibition against serum TXB2 production after 24 hr r at dose 10 mg/kg by oral administration in rat | 1985 | Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
| Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids. |
| AID93431 | Antagonistic activity against human platelet aggregation induced by U-46,619. | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. |
| AID212615 | In vitro inhibition of TXB2 production by incubating prostaglandin H2 with human platelet microsomes. | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
| Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs. |
| AID183549 | Inhibition of thromboxane A2 production in whole blood of rats, 4 hr after a peroral dose of 0.1 mg/kg | 1989 | Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
| Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives. |
| AID166529 | The concentration required to reduce by 50% the amount of LTB4 formed by RBL-1 cells | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species. Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives. |
| AID225763 | In vitro inhibition of U-46619 (3 uM) -induced human platelet aggregation | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
| Dibenzoxepin derivatives: thromboxane A2 synthase inhibition and thromboxane A2 receptor antagonism combined in one molecule. |
| AID227631 | Tested for the effect at 30 mg/kg through peroral route on rat blood urea nitrogen, 48 hr after reperfusion; (p<0.05) | 1993 | Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
| Dibenzoxepin derivatives: thromboxane A2 synthase inhibition and thromboxane A2 receptor antagonism combined in one molecule. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
| Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID212979 | Thromboxane synthase inhibitor (TxSI) activity was assessed by ex vivo inhibition of serum TXB2 production in rat after oral administration | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
| Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). |
| AID212971 | In vitro inhibition of thromboxane synthase (TXA2) in human platelet microsomes [reduced formation of TXB2 from prostaglandin H2(PGH2)] | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
| Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). |
| AID114743 | Tested in vivo for Platelet activating factor (PAF) antagonist in mice after Intravenous administration using PAF-induced death assay; NT = not tested | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
| Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). |
| AID178240 | Inhibition of serum TXB2 production in the rats after intravenous administration | 2002 | Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
| Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). |
| AID113512 | In vivo for Platelet activating factor (PAF) antagonistic activity in mice after oral administration using PAF-induced death assay; NT = not tested | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
| Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). |
| AID212629 | Thromboxane A2 synthase inhibitory activity was measured from inhibition of thromboxane B2 production in human platelet microsomes | 2002 | Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
| Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). |
| AID210469 | Inhibitory activity against thromboxane B2 formation (TXA2 synthase) by incubating prostaglandin H2 (PGH-2) with horse platelet microsomes | 1985 | Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
| Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids. |
| AID128157 | Ability to protect mice from the lethal effect of Platelet activating factor on po administration of compound; Not tested | 2002 | Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
| Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). |
| AID212976 | Thromboxane synthase inhibitor (TxSI) activity assessed by ex vivo inhibition of serum TXB2 production in rat after Intravenous administration | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
| Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). |
| AID160940 | Tested in vitro for the inhibition of Platelet activating factor (PAF) induced platelet aggregation in rabbit platelet rich plasma (PRP); NT=Not tested | 2002 | Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
| Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). |
| AID165600 | The compound was tested for inhibition of Platelet activating factor (PAF) induced platelet aggregation in rabbit platelet rich plasma; Not tested | 2002 | Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
| Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). |
| AID132330 | Ability to protect mice from the lethal effect of Platelet activating factor on iv administration of compound; Not tested | 2002 | Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
| Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). |
| AID178241 | Inhibition of serum TXB2 production in the rats after peroral administration | 2002 | Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
| Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |